437 related articles for article (PubMed ID: 8902262)
1. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
2. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
3. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
4. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
5. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
6. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
Shimada T; Mernaugh RL; Guengerich FP
Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
[TBL] [Abstract][Full Text] [Related]
7. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of inhibitor-bound P450BM-3 reveals open conformation of substrate access channel.
Haines DC; Chen B; Tomchick DR; Bondlela M; Hegde A; Machius M; Peterson JA
Biochemistry; 2008 Mar; 47(12):3662-70. PubMed ID: 18298086
[TBL] [Abstract][Full Text] [Related]
11. How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms.
Lüdemann SK; Lounnas V; Wade RC
J Mol Biol; 2000 Nov; 303(5):797-811. PubMed ID: 11061976
[TBL] [Abstract][Full Text] [Related]
12. Active site analysis of P450 enzymes: comparative magnetic circular dichroism spectroscopy.
Andersson LA; Johnson AK; Peterson JA
Arch Biochem Biophys; 1997 Sep; 345(1):79-87. PubMed ID: 9281314
[TBL] [Abstract][Full Text] [Related]
13. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF.
Cupp-Vickery JR; Garcia C; Hofacre A; McGee-Estrada K
J Mol Biol; 2001 Aug; 311(1):101-10. PubMed ID: 11469860
[TBL] [Abstract][Full Text] [Related]
14. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
15. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
16. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
[TBL] [Abstract][Full Text] [Related]
17. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN
J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197
[TBL] [Abstract][Full Text] [Related]
18. Use of kinetic isotope effects to delineate the role of phenylalanine 87 in P450(BM-3).
Rock DA; Boitano AE; Wahlstrom JL; Rock DA; Jones JP
Bioorg Chem; 2002 Apr; 30(2):107-18. PubMed ID: 12020135
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 May; 42(9):1515-24. PubMed ID: 10229622
[TBL] [Abstract][Full Text] [Related]
20. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
Hanna IH; Kim MS; Guengerich FP
Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]